Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for difficult-to-treat infections MARINA DEL REY, Cali... Biopharmaceuticals, FDA Armata Pharmaceuticals, bacteriophage, Staphylococcus aureus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news